drugset
drugset / Trial / NCT05306132

Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067

NCT05306132 ↗

Phase 1 Recruiting 150 enrolled Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is the first-in-human of ASKC202, which is an open-label, non-randomized, multicenter study with a dose escalation phase and a dose expansion phase.

Timeline

Start
2022-08-08
Primary completion
2026-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ASK120067 Unknown 80 mg Oral
Subject ASKC202 Unknown 50 mg Oral
Subject ASKC202 Unknown 150 mg Oral
Subject ASKC202 Unknown 200 mg Oral
Subject ASKC202 Unknown 600 mg Oral

Indications

neoplasm